Description of Collaborative Activity: |
This Quartely meeting to enhance communication between the National Cancer Institute (NCI) and the Food and Drug Administration (FDA), thereby expediting the development of new anti-cancer agents. General topics discussed include patient safety, clinical efficacy, and regulatory pathways to licensure, as well as an understanding of the operations of the sister agencies. |
